APRIL and BCMA promote human multiple myeloma growth and immunosuppression in the bone marrow microenvironment. - Wikidata - wikimedia - TriplyDB

APRIL and BCMA promote human multiple myeloma growth and immunosuppression in the bone marrow microenvironment.

APRIL and BCMA promote human multiple myeloma growth and immunosuppression in the bone marrow microenvironment.

http://www.wikidata.org/entity/Q37035836

about

A look backward and forward in the regulatory and treatment history of multiple myeloma: Approval of novel-novel agents, new drug development, and longer patient survival.Interferon-alpha-based immunotherapies in the treatment of B cell-derived hematologic neoplasms in today's treat-to-target era cDNA-library testing identifies transforming genes cooperating with c-myc in mouse pre-B cells.Neutral tumor evolution in myeloma is associated with poor prognosis.Changes in uninvolved immunoglobulins during induction therapy for newly diagnosed multiple myeloma.Monoclonal antibody therapy in multiple myeloma.Osteoclasts promote immune suppressive microenvironment in multiple myeloma: therapeutic implication.Downregulation of LRIG2 expression inhibits angiogenesis of glioma via EGFR/VEGF-A pathway.Progress and Paradigms in Multiple Myeloma.Human Plasmacytoid Dendritic Cells Display and Shed B Cell Maturation Antigen upon TLR Engagement.Monoclonal Antibody Therapies for Hematological Malignancies: Not Just Lineage-Specific Targets.The Role of B-Cell Maturation Antigen in the Biology and Management of, and as a Potential Therapeutic Target in, Multiple Myeloma.A novel agent SL-401 induces anti-myeloma activity by targeting plasmacytoid dendritic cells, osteoclastogenesis and cancer stem-like cells.A novel BCMA/CD3 bispecific T-cell engager for the treatment of multiple myeloma induces selective lysis in vitro and in vivo.Modulating PD-L1 expression in multiple myeloma: an alternative strategy to target the PD-1/PD-L1 pathway.NF-κB in Hematological Malignancies.Effective Targeting of Multiple B-Cell Maturation Antigen-Expressing Hematological Malignances by Anti-B-Cell Maturation Antigen Chimeric Antigen Receptor T Cells.Pre-clinical validation of B cell maturation antigen (BCMA) as a target for T cell immunotherapy of multiple myeloma.Development and Evaluation of an Optimal Human Single-Chain Variable Fragment-Derived BCMA-Targeted CAR T Cell Vector Clinical impact of serum soluble SLAMF7 in multiple myeloma Targeting B Cell Maturation Antigen (BCMA) in Multiple Myeloma: Potential Uses of BCMA-Based Immunotherapy Osteoclast Immunosuppressive Effects in Multiple Myeloma: Role of Programmed Cell Death Ligand 1

P2860

Q30239781-AF282D85-1DAE-4DFF-8DAF-41BF2CBAF43B Q33909086-8A2ED068-2BA2-418D-BF4B-0E2BD62F2D41 Q36107429-1F446089-6C91-4FFF-B067-8A6900D2ED78 Q38615431-25BD742A-95B3-46D5-BB29-F14A62E2A7AF Q38722312-128AB094-86A2-4DD9-820D-E5DD69B40751 Q38956372-D4C5C193-C097-4922-94B6-7E914B3D6D6A Q41168758-095A68B0-03D7-482B-A5F4-D44B210AFD1E Q41701946-1CD6E929-B8EB-43C6-B995-8D420AC485D1 Q44694137-15AEAC7D-3ABB-413C-AC41-3ED746823A00 Q48138391-E2EEF5BE-B752-4C31-83ED-AE926E9DF24F Q49539698-F5205DBB-140A-4FA6-A297-3019FB04D702 Q49913606-153477F6-BC69-4FEC-A653-6B725122578A Q51016220-4ACF171E-C5CD-44A8-B2DA-E52A2A6F83A4 Q51233981-8928503F-1EF8-4E39-BBB8-6DBDD140ACAD Q52630284-7D4717AE-1D4B-42AA-B1E7-7503CAD8A512 Q54147337-C40C4B9D-DE0E-411A-8791-FAC31E9ADECF Q55035666-B0BF6411-B3B5-45E4-AEF0-19BAC6A6FD99 Q55251612-466AF971-2D26-440B-8BC0-A25EDE2C4B52 Q56889227-DAEE76CD-7FC1-402B-8818-9E85A4617D63 Q58582611-66491C7F-62D5-452D-9083-D49769E63A61 Q58790069-28AB4494-153A-4C07-870B-1282663DD14C Q58790080-F962AF29-4E00-4531-ADFE-019FF48EF1F5

P2860

APRIL and BCMA promote human multiple myeloma growth and immunosuppression in the bone marrow microenvironment.

http://www.wikidata.org/entity/Q37035836

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 28 April 2016

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

APRIL and BCMA promote human m ...... bone marrow microenvironment.

@en

APRIL and BCMA promote human m ...... bone marrow microenvironment.

@nl

type

label

APRIL and BCMA promote human m ...... bone marrow microenvironment.

@en

APRIL and BCMA promote human m ...... bone marrow microenvironment.

@nl

prefLabel

APRIL and BCMA promote human m ...... bone marrow microenvironment.

@en

APRIL and BCMA promote human m ...... bone marrow microenvironment.

@nl

P1433

Q37035836-B4B23C49-3218-4682-8E4D-EBC564953324

P1476

Q37035836-C6ED3EFD-990C-423A-9C36-7C4E86A4BBAB

P2093

Q37035836-168E2240-000B-4EC9-B259-27F4CB11C767

Q37035836-2320B2CC-7C07-4659-AC60-39F41BDECB9F

Q37035836-36A0CFF3-9CF1-4E0B-B819-D30CCB1E58A3

Q37035836-391F7C94-DA10-4E46-B4AE-2CE0B2D1421B

Q37035836-6006CCA5-517E-4970-8150-09601BAECCCA

Q37035836-6DD42111-60A8-42F0-9201-E06330624EFD

Q37035836-8890145F-431A-4BF9-B766-F3223C132313

Q37035836-CB6F364A-6EDD-458B-A30B-9771B4DAA725

Q37035836-CDABF878-CAF3-4FED-A463-A49FC3B80628

Q37035836-D24907E9-68D4-4BC7-9624-35404DAF9C46

P2860

Q37035836-012D9BDE-8788-44B3-BCEC-EC4AE014BBB8

Q37035836-02F2E407-9806-4B77-A3B7-FE3E95BCE49F

Q37035836-0400DCDE-F8F9-496A-8A88-129EB8437E50

Q37035836-0CA80E21-47E2-4BF1-B628-3BD93DCF15C4

Q37035836-0E80D620-68C5-4627-9FF9-ECD23598BA91

Q37035836-129DB42E-D7A8-404B-B4E4-6114896643D7

Q37035836-18C66662-ED44-40D2-816C-B14DEC93A12B

Q37035836-19DD036F-5FD5-4ED0-BF7E-B411FF5837AD

Q37035836-1A73294E-9A38-4756-B54A-22366E6FEE0A

Q37035836-1EEF554E-4A79-4FC3-8D89-A274D5C18843

P304

Q37035836-7857F263-B420-49DF-ABC8-679E85C84C64

P31

Q37035836-934803D7-491E-4E7A-9CFD-6039B45FD4C6

P356

Q37035836-11D0A878-67C4-4660-BACD-4D97BE5F04DF

P407

Q37035836-F2BD9937-10DF-4661-9872-D954167E6854

P433

Q37035836-BDECD0CA-7714-41EE-990B-FA226EFF6B29

P478

Q37035836-68C38857-76AE-4AC1-8CD6-54307F0AFC34

P50

Q37035836-544A03E0-5B08-41EE-8334-719C412DD559

Q37035836-735AB2C7-74AD-4060-B0F6-3926AE317FDD

Q37035836-7E5E93E7-83D5-4AD0-9572-AE5E2E3D60DA

P577

Q37035836-FC66E593-507F-4884-AC0B-CE3DDCCABC59

P698

Q37035836-3DAAEF4B-93DA-467E-8631-26B34A1F4818

P921

Q37035836-283CE636-B08A-40AA-ADEB-C504813EBE14

P932

Q37035836-9714505A-12F4-4FFA-8C4A-D60566FAFFBD

P356

BLOOD-2016-01-691162

P1433

P1476

APRIL and BCMA promote human m ...... e bone marrow microenvironment

@en

P2093

Andrea van Elsas

http://www.w3.org/2001/XMLSchema#string

Antonia Cagnetta

http://www.w3.org/2001/XMLSchema#string

Chirag Acharya

http://www.w3.org/2001/XMLSchema#string

Gang An

http://www.w3.org/2001/XMLSchema#string

Hans van Eenennaam

http://www.w3.org/2001/XMLSchema#string

Kenneth Wen

http://www.w3.org/2001/XMLSchema#string

Lugui Qiu

http://www.w3.org/2001/XMLSchema#string

Michele Moschetta

http://www.w3.org/2001/XMLSchema#string

Mike Y Zhong

http://www.w3.org/2001/XMLSchema#string

Nikhil Munshi

http://www.w3.org/2001/XMLSchema#string

P2860

The level of TACI gene expression in myeloma cells is associated with a signature of microenvironment dependence versus a plasmablastic signature

Hodgkin lymphoma cells express TACI and BCMA receptors and generate survival and proliferation signals in response to BAFF and APRIL

Small-molecule SMAC mimetics as new cancer therapeutics

Heparan sulfate proteoglycans in the control of B cell development and the pathogenesis of multiple myeloma

Expression of BCMA, TACI, and BAFF-R in multiple myeloma: a mechanism for growth and survival

APRIL is critical for plasmablast survival in the bone marrow and poorly expressed by early-life bone marrow stromal cells

Targeting CD38 with Daratumumab Monotherapy in Multiple Myeloma

ACK1 tyrosine kinase: targeted inhibition to block cancer cell proliferation

APRIL-deficient mice have normal immune system development

BCMA is essential for the survival of long-lived bone marrow plasma cells

P304

3225-3236

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1182/BLOOD-2016-01-691162

http://www.w3.org/2001/XMLSchema#string

P407

P433

25

http://www.w3.org/2001/XMLSchema#string

P478

127

http://www.w3.org/2001/XMLSchema#string

P50

Kenneth C Anderson

Paul G Richardson

P577

2016-04-28T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27127303

http://www.w3.org/2001/XMLSchema#string

P921

immunosuppression

P932

4920023

http://www.w3.org/2001/XMLSchema#string